Biomarkers Enhance Astra Zeneca’s Clinical Trial Successes

Tags: , ,


Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug Therapeutic Vaccinedevelopment process.  The huge investment in a new testing paradigm to address the new types of therapeutics was worth it for AZ, and will benefit not only all companies in the pharmaceutical industry, but mankind since we can expect to see an increase in the number of efficacious therapies sooner rather than later!

Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework.  David Cook,Dearg Brown, Robert Alexander, Ruth March, Paul Morgan, Gemma Satterthwaite & Menelas N. Pangalos.  Nature Reviews Drug Discovery (2014).  DOI: doi:10.1038/nrd4309. Published online 16 May 2014

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>